capivasertib,AZD5363
astrazeneca,otsuka
['mbc', 'capivasertib']
 faktion trial: capivasertib + fulv in pretreated hr+/her2- #mbc confirms to be a promising combo (&gt; in the pi3k/akt/pten pathway mutatation):
- pfs: 10.3 vs 4.8 mo (hr 0.56, p=0.002)
- os: 29.3 vs 23.4 mo (hr 0
66, p=0.035 safety! #asco22 